Skip to main content

Advertisement

Log in

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) combined have been recognized as standard of care for treatment of a subset of patients with peritoneal carcinomatosis (PC). The aim of CRS is to eliminate all macroscopic disease through a series of visceral resections followed by targeting any residual microscopic disease with intraperitoneal chemotherapy, exposing the peritoneal surfaces to a high concentration of chemotherapy with a lower systemic toxicity. Different regimes of intraperitoneal chemotherapy include HIPEC, early postoperative intraperitoneal chemotherapy (EPIC) and bidirectional chemotherapy. The efficacy and modality of treatment with intraperitoneal chemotherapy is dependent on multiple factors including the chosen cytotoxic agent and its pharmacokinetics and pharmacodynamics. There is no standardized methodology for intraperitoneal chemotherapy administration. This review will discuss the pharmacological principles of the various intraperitoneal chemotherapy techniques.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Elias D, Glehen O, Gilly F, et al. (2008). Carcinose peritoneles d’origine digestive et primitive. In: Rapport du 110eme congress de l’AFC. Arnette: Wolters Kluwer France.

  2. Sugarbaker PH (2003) Peritonectomy procedures. Surg Oncol Clin N Am 12:703–727

    Article  PubMed  Google Scholar 

  3. Trimble EL, Thompson S, Christian MC, Minasian L (2008) Intraperitoneal chemotherapy for women with ovarian cancer. The Oncologist 13(4):403–409

    Article  CAS  PubMed  Google Scholar 

  4. Yan TD, Welch L, Black D, et al. (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827–834

    Article  CAS  PubMed  Google Scholar 

  5. Yan TD, Black D, Savady R, (2006) et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol;24:4011–4019.

  6. Yonemura Y, Bando E, Kawamura T, et al. (2007) Cytoreduction and intraperitoneal chemotherapy for carcinomatosis from gastric cancer. Cancer Treat Res 134:357–373

    CAS  PubMed  Google Scholar 

  7. Kusamura S, Elias D, Baratti D, (2008) et al. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol;98:247–252.

  8. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. De Bree E, Tsiftsis DD (2007) Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res 169:39–51

    PubMed  Google Scholar 

  10. Elias D, Antoun S, Goharin A, (2001) et al. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig;1:431–439.

  11. Deraco M, Glehen O, Helm CW, Morris DL, Van der Speeten K (2013) Sugarbaker PH. In: Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas. Cine-med, Canada

    Google Scholar 

  12. Van der Speeten K, Stuart OA, Caillot JL, (2011) et al. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol;68:147–156.

  13. Elias D, Lefevre JH, Chevalier J, (2009) et al. Complete cytoreductive surgery plus intraperitoneal chemohypethermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol;27:681–685.

  14. De Somer F, Ceelen W, Delanghe J, et al. (2008) Severe hyponatremia, hyperglycemia and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:61–66

    PubMed  Google Scholar 

  15. Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3):1–6

    CAS  PubMed  Google Scholar 

  16. Yan TD, Black D, Sugarbaker PH, et al. (2007) A systematic review and metaanalysis of the randomised controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14:2702–2713

    Article  PubMed  Google Scholar 

  17. Markman M, Bundy BN, Alberts DS, et al. (2001) Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007

    CAS  PubMed  Google Scholar 

  18. Hayes-Jordan A, Owusu-Agyemang P, Green H (2012) Anaesthetic management and renal function in paediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. Ann Surg Oncol 19:2652–2656

    Article  PubMed  Google Scholar 

  19. Glehen O, Cotte E, Kusamura S, et al. (2008) Hyperthemic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol 98:242–246

    Article  PubMed  Google Scholar 

  20. Jacquet P, Averbach A, Stephens AD, et al. (1998) Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-flurouracil: pharmacokinetic studies. Oncology 55:130–138

    Article  CAS  PubMed  Google Scholar 

  21. Glehen O, Sugarbaker PH, Elias D, et al. (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. A multi-institutional study. J Clin Oncol 22:3284–3292

    Article  CAS  PubMed  Google Scholar 

  22. Elias D, Benizri E, Di Pietrantonio D, et al. (2007) Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 14:509–514

    Article  PubMed  Google Scholar 

  23. Sammartino P, Accarpio F, Cornal T, et al. (2015) Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) combined. In: Di Georgio A & Pinto E. Treatment of peritoneal surface malignancies: updates in surgery. Pg 107–127.

  24. Mathe G, Kidani Y, Seglguchi M, et al. (1989) Oxalato-platinum or I-OHP, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomedicine and Pharmacotherapy. 43:237–250

    Article  CAS  PubMed  Google Scholar 

  25. De Gramont A, Tournigand C, Louvet C, et al. (1997) Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX) in pretreated patients with metastatic advanced cancer the GERCOD. La Revuede Medecine Interne/Fondee Par La Societe Nationale Francaisede Medecine Interne 18:769–775

    Google Scholar 

  26. Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH (2010) Pharmacology of perioperative 5-fluorouracil. J Surg Oncol 102(7):730–735

    Article  PubMed  Google Scholar 

  27. Jacquet P, Averbach AM, Stuart OA, Chang D, Sugarbaker PH (1998) Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism and tissue distribution in a rat model. Cancer Chemother Pharmacol 41:147–154

    Article  CAS  PubMed  Google Scholar 

  28. Yonemura Y, Bandou E, Sawa T, et al. (2006) Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol 32:661–665

    Article  CAS  PubMed  Google Scholar 

  29. Sugarbaker PH (1996) Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Cancer Treat Res 82:317–325

    Article  CAS  PubMed  Google Scholar 

  30. Zylberberg B, Dormont D, Janklewicz S, et al. (2001) Response to neoadjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIC ovarian cancer. Eur J Gynaecol Oncol 22:40–45

    CAS  PubMed  Google Scholar 

  31. Esquivel J, Vidal-Jove J, Steves MA, et al. (1993) Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 113:631–636

    CAS  PubMed  Google Scholar 

  32. Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier. Cancer Treat Res 82:53–63

    Article  CAS  PubMed  Google Scholar 

  33. Jones RB, Myers CE, Guarino AM, et al. (1978) High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. pharmacologic basis and early results. Cancer Chemother Pharmacol 1:161–166

    Article  CAS  PubMed  Google Scholar 

  34. MacArthur KM, Nicholl MB (2013) Principles and innovations in peritoneal surface malignancy treatment. World J Oncol 4(3):129–136

    Google Scholar 

  35. Dedrick RL, Myers CE, Bungay PM, et al. (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11

    CAS  PubMed  Google Scholar 

  36. Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G (2010) Hyperthemic intraperitoneal chemotherapy: rationale and technique. WJGO 2(2):68–75

    Article  PubMed  PubMed Central  Google Scholar 

  37. Pillai K, Akhter J, Chua T, Morris DL (2014) A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei. Int J Cancer 134:478–486

    Article  PubMed  Google Scholar 

  38. Speyer JL, Sugarbaker PH, Collins JM, et al. (1981) Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922

    CAS  PubMed  Google Scholar 

  39. Elias D, Bonnay M, Puizillou JM, et al. (2002) Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267–272

    Article  CAS  PubMed  Google Scholar 

  40. Sugarbaker PH, Mora JT, Carmignani P, et al. (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10:112–122

    Article  CAS  PubMed  Google Scholar 

  41. Keshaviah P, Emerson PF, Vonesh EF, et al. (1994) Relationship between body size, fill volume and mass transfer area coefficient in peritoneal dialysis. J Am Soc Nephrol 4:1820–1826

    CAS  PubMed  Google Scholar 

  42. Sticca RP, Dach BW (2003) Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 12(3):689–701

    Article  PubMed  Google Scholar 

  43. Piche N, Leblond FA, Sideris L, et al. (2001) Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis. A study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann. Surg. 254:138–144

    Article  Google Scholar 

  44. Leunig M, Goetz AE, Dellian M, et al. (1992) Interstitial fluid pressure in solid tumours following hyperthermia: possible correlation with therapeutic response. Cancer Res 52:487–490

    CAS  PubMed  Google Scholar 

  45. Esquis P, Consolo D, Magnin G, et al. (2006) High intraabdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental carcinomatosis. Ann Surg 244:106–112

    Article  PubMed  PubMed Central  Google Scholar 

  46. Glehen O, Osinsky D, Cotte E, et al. (2003) Intraperitoneal chemohyperthemia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10:863–869

    Article  CAS  PubMed  Google Scholar 

  47. Yonemura Y, Fujimura T, Fushida S, et al. (1991) Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 15:530–536

    Article  CAS  PubMed  Google Scholar 

  48. Gonzalez-Bayon L, Gonzalez-Moreno S, Ortega-Perez G (2006) Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. Eur J Surg Oncol 32:619–624

    Article  CAS  PubMed  Google Scholar 

  49. Halkia E, Tsochrinis A, Vassiliadou DT, et al. (2015) Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol 610597

  50. Ortega-Deballon O, Facy O, Jambet S, et al. (2010) Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol 17(7):1957–1963

    Article  PubMed  Google Scholar 

  51. Stephens AD, Alderman R, Chang D, et al. (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6:790–796

    Article  CAS  PubMed  Google Scholar 

  52. Stuart O, Stephens AD, Welch L, et al. (2002) Safety monitoring of the coliseum technique for heated intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol 9:186–191

    Article  PubMed  Google Scholar 

  53. Garofalo A, Valle M, Garcia J, et al. (2006) Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. EJSO 32:682–685

    Article  CAS  PubMed  Google Scholar 

  54. Valle M, Van der Speeten K, Garofalo A (2009) Laparoscopic hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100:331–334

    Article  CAS  PubMed  Google Scholar 

  55. Valle SJ, Alzahrani N, Alzahrani S, Liauw W, Morris DL (2015) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg 23:176--180

  56. Esquivel J, Averbach A, Chua TC (2011) Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg 253:764–768

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to S. J. Valle or D. L. Morris.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Valle, S.J., Alzahrani, N.A., Liauw, W. et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy. Indian J Surg Oncol 7, 152–159 (2016). https://doi.org/10.1007/s13193-016-0498-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-016-0498-0

Keywords

Navigation